In a revealing investigation, the U.S. Drug Enforcement Administration (DEA) was found to have permitted the distribution of hundreds of thousands of fentanyl pills in New Mexico. This controversial decision was part of a broader strategy aimed at building larger federal prosecutions. The detailed account, co-written by Jim Mustian and Joshua Goodman, was based on an extensive review of internal DEA records and interviews with current and former agents, including a whistleblower named David Howell.
The whistleblower complaint, which accused the DEA of allowing fentanyl to flood the streets of New Mexico, was initially overlooked when it was sent to the White House in September. Mustian discovered a critical oversight in the heavily redacted report; the name of the whistleblower had not been sufficiently concealed. This clue enabled him to reach out to DEA agents on LinkedIn, eventually leading him to Howell.
DEA's tactic of allowing drugs to ‘walk’ to ensnare larger criminals has faced criticism, especially regarding fentanyl. The drug’s extreme potency poses a significant public safety risk, with just a few grams being lethal. The DEA has been actively campaigning to raise awareness of these dangers through its “One Pill Can Kill” initiative, which highlights the risks associated with counterfeit pills. In a notable example from 2023, DEA agents monitored a shipment of 74,000 fentanyl pills at a mobile home park in Albuquerque but chose not to seize it, a decision that Howell likened to distributing lethal pills to an entire football stadium.
Federal officials defended the decision by arguing that allowing these drugs to remain on the streets could lead to capturing bigger dealers, a strategy U.S. attorney Alex Uballez claimed ultimately saves more lives. However, the DEA's statement contradicted public assertions, stating that speculations of the agency knowingly permitting fentanyl distribution were false and mischaracterized the facts. They maintained their investigative decisions were lawful and consistent with departmental guidance.
Throughout the reporting process, Mustian noted the significant gap between law enforcement activities and public awareness. The DEA's considerable discretion in decision-making regarding public safety issues often operates behind closed doors, with taxpayers left in the dark. Records pertaining to such operations would typically not be accessible via the Freedom of Information Act, illustrating a lack of transparency in DEA practices.
David Howell, a 19-year veteran of the DEA, raised the issue with his superiors through a formal whistleblower complaint filed with the Office of Special Counsel (OSC). He included documentation such as reports, emails, and messages that indicated discussions among agents about significant drug transactions they chose not to interrupt. The OSC initially expressed concern, indicating a “substantial likelihood of wrongdoing,” and urged a Justice Department investigation.
However, the Department of Justice's Office of Professional Responsibility eventually concluded that the DEA's actions were reasonable and did not pose a specific danger to public health. Critics, including Howell, argued that internal investigations did not adequately address the central issue of whether massive fentanyl distributions were permissible under their operational protocols.
The investigation opens up complex questions regarding the balance between law enforcement strategies and the imperative to protect public health, especially in the context of the growing fentanyl crisis.
